Biogen

The GLP is committed to full transparency. Download and review our 2020 Annual Report.

Our interactive GLP global map explains the status of each country’s regulations for human and agricultural gene editing and gene drives.

This GLP project maps contributions by foundations to anti-biotech activists and compares it to pro-GMO industry spending.

November 5, 2019

I worked on and around aducanumab, an experimental treatment for Alzheimer’s, for years during my time at Biogen. I thought ...

October 24, 2019

An experimental treatment for Alzheimer's disease is headed to the Food and Drug Administration for approval—despite the fact that it ...

March 22, 2019

Alzheimer’s disease has beaten back another effort to tame it. Biogen and its Japanese pharma partner Eisai said [March 21] ...

Newsletter Subscription